Microfluidic cell fragmentation for mechanical phenotyping of cancer cells INTRODUCTION
The hemodynamic transport of circulating tumor cells (CTCs) is an essential step in cancer metastasis. [1] [2] [3] [4] It is estimated that for every gram of tumor, about a million cells are shed per day into the blood stream. [5] [6] [7] Despite the hematogenous dissemination of such a large number of CTCs, less than 0.01% survive to produce metastases. [8] [9] [10] [11] Thus, survival of CTCs in blood circulation is a critical step for the occurrence of metastases.
The destruction of CTCs in circulation can be due to factors such as cellular anoikis and host defense mechanisms. 12, 13 In contrast to these cytocidal factors, several studies show that physical forces can also destroy CTCs, contributing significantly to metastatic inefficiency. [14] [15] [16] Further direct evidence comes from in vivo imaging in mouse models which show that the tumor cells arrested in the microvasculature undergo fragmentation due to fluid stresses. [17] [18] [19] [20] [21] [22] The degree of fragmentation was found to depend on the organ site and the type of cell lines used in the animal studies. 14, 18, 23 Inspired by the fact that CTCs are prone to mechanical destruction at microcapillary junctions, in this study we report a new microfluidic method for phenotyping cancer cells based on their fragmentation characteristics. As shown in Fig. 1 , the method involves flow-induced rupture of cancer cells at a micropillar-based bifurcation, where a tumor cell is strongly stretched by fluid forces ultimately causing a portion of the cytoplasm to pinch-off. Our micropillar design builds on geometries that have been used to study droplet breakup in microfluidic devices. [24] [25] [26] The method proposed here is a new addition to the growing class of techniques that harness the unique capabilities of microfluidics to phenotype tumor cells based on deformability. [27] [28] [29] [30] Notable examples include squeezing of cells through microconstrictions and recording entry/ passage times, [31] [32] [33] tracking changes to cell shape under strong extensional forces, 34, 35 and deformability based margination. 36, 37 However, unlike existing methods, our approach has the potential to reveal information about the ultimate fate of tumor cells, i.e., whether a tumor cell has metastatic capacity or will succumb to mechanical destruction and cell death in microcirculation. Indeed, our results show that highly metastatic cells take longer to fragment than lowly metastatic cells, suggesting that in the dynamically fluctuating microcirculatory environment, metastatic CTCs might be less prone to fragmentation.
METHODS
Microfluidic devices were fabricated in polydimethyl(siloxane) using soft lithography. 38 The device layout consists of ten entry channels that are connected in parallel to a common inlet and outlet ( Fig. 1(a) ). Each of the entry channels contains a micropillar obstacle that allows flow bifurcation. The entry channel has a width of 21.1 6 0.8 lm. The obstacle has a width of 10.9 6 0.7 lm and a length of 24.7 6 1.2 lm. The gap between the micropillar and the channel wall is 4.8 6 0.4 lm. All the structures in the microfluidic device have a uniform height of 14.5 6 0.6 lm.
Two types of prostate cancer cells were used in this study-lowly metastatic LNCaP cells and highly metastatic CL2 cells. Both cells were cultured in RPMI-1640 medium (Cellgro) supplemented by 5% FBS (Fetal Bovine Serum), 1 mM L-Glutamine, 1 mM non-essential amino acids, 2 mM Sodium Pyruvate, and 1% Penicillin/Streptomycin. Cell culture chemicals were purchased from Fisher Scientific.
The microfluidic device was mounted on an inverted microscope (IX-70, Olympus Inc.). A constant pressure drop was imposed across the device using a pressure controller (MFC8-FLEX4C, Fluigent Inc.). Images were recorded with a 20Â magnification objective (1 pixel ¼ 0.915 lm) using a high-speed camera (Phantom V39, Vision Research Inc.) at 500-1500 frames per second in brightfield mode. Images were analyzed manually using Image J v.1.49.
All experiments were conducted at a fixed pressure drop of 2666 Pa ( ¼ 20 mm Hg), which is within the range of intravascular pressure. 39, 40 This pressure drop produces cell velocities of 12 6 7 mm/s. The fluid shear stress corresponding to this pressure drop in the micropillar gap is estimated to be %7 Pa.
RESULTS AND DISCUSSION
In both tumor cell types, we find that the fragmentation process generally involves four steps, as shown in Fig. 1(b) . When a tumor cell arrives at the obstacle (Fig. 1(b-i) , Multimedia view), due to flow bifurcation it is pulled into the clearance between the pillar and the channel wall producing fingers (Fig. 1(b-ii) , Multimedia view). These fingers continue to elongate over time, followed by necking of the finger (Fig. 1(b-iii) , Multimedia view). The neck thins down ultimately causing the cytoplasmic finger to rupture and separate from the cell body (Fig. 1(b-iv) , Multimedia view).
For the highly metastatic CL2 cancer cells, we find that out of 66 cells analyzed, 24 (36.4%) undergo fragmentation, while 42 (63.6%) cells squeeze through. Likewise, with the lowly metastatic LNCaP cells, out of 58 cells analyzed, 26 (45%) undergo fragmentation, while 32 (55%) cells squeeze through. These results suggest that the fragmentation is not a rare event, but a considerable number of tumor cells can rupture given suitable geometric and flow conditions.
We next investigated whether the size of the tumor cells influences their ability to fragment, since it is possible that too small a size will allow the cell to squeeze through rather than be arrested and fragmented. Consistent with this expectation, in Fig. 2 , we show for both cell types, the peak of the cell diameter distribution is lower for cells that do not fragment than those that undergo fragmentation. Interestingly in both cell lines, we find a considerable overlap in the size distribution of fragmented and non-fragmented cells. In this overlap region (CL2: 16-20 lm; LNCaP: 15-19 lm), cells of similar size can either fragment or escape fragmentation by squeezing through the micropillar gap. Thus, our results show that the size alone does not influence fragmentability, but also mechanical properties of tumor cells play an important role.
Finally, we test whether the metastatic potential difference in the two cell lines can be distinguished using microfluidic fragmentation. We define two metrics-fragmentation time and excess area-to characterize the fragmentation process. Fragmentation time is the time difference between when the cell first encounters the micropillar (Fig. 1(b-i) ) and when a finger separates ( Fig. 1(b-iv) ). We also measure the cell surface areas at these initial and final time points (A o , A f ) and define the excess area, D ¼ (A f À A o )/A o . Of note is that the cell surface area we measure is actually the projected area (since our imaging is two-dimensional); therefore, D is an approximate measure of the degree to which the cell and its membrane are stretched. As shown in Fig. 3 , we observe that the fragmentation time is higher for the more invasive cell line CL2. The excess area, however, is less for CL2 than LNCaP cells, suggesting that the rate of membrane stretching is lower in highly metastatic cells. Thus, our fragmentation metrics are capable of differentiating prostate cancer cell lines of different metastatic potential.
In summary, we develop a new method for phenotyping cancer cells based on their fragmentation characteristics. In contrast to flow-induced squeezing of cancer cells, from a fundamental point of view, the mechanical deformation of the membrane and cytoskeleton during fragmentation is extreme, potentially lending new insights into the nonlinear mechanics of tumor cells. Additional studies are also needed to ascertain what role do mechanical properties of membrane, cytoskeleton, and nucleus play in the fragmentation process; and whether fragmented tumor cells are viable. From a methods perspective, microfluidic cell fragmentation can have a significant impact in a variety of areas, including identifying invasive phenotypes in patient samples, screening drug compounds, and generating new insights into cancer metastasis.
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